Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies

The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026